Adaptive Biotechnologies enters the post-earnings period with a notable internal tension: short sellers are stepping back, yet the company's own President and COO has been selling shares every single trading day for the past two weeks.
Short interest has been on a clear downward path. At roughly 6.7% of the free float, it has fallen from a peak near 7.7% in late March — a near-13% reduction in shorted shares over the past month. The borrow market reflects this easing: cost to borrow has dropped more than 55% versus a month ago and now sits at just 0.36%, a negligible rate that signals no stress in the lending pool. Availability is also exceptionally loose at around 1,800% of short interest, meaning there are roughly eighteen times as many shares available to borrow as are currently shorted. Shorts are not squeezed, not crowded, and not paying a premium to hold the position. The ORTEX short score of 45.2 is mid-range and has drifted lower over the past week, reinforcing the picture of a position that is being wound down rather than built.
Options positioning tells a similar story of muted caution. The put/call ratio of 0.26 is actually fractionally below its 20-day average of 0.28 — statistically unremarkable, essentially flat. That ratio is far from the 52-week high of 1.57, recorded during peak uncertainty earlier in the year. Options traders are not paying up for downside protection right now.
The standout data point this week is the insider activity. President and COO Julie Rubinstein sold shares on every trading day from April 14 through April 27 — ten consecutive sessions, totalling roughly 184,000 shares and approximately $2.5 million in proceeds. The sales occurred in a narrow price range between $13.74 and $14.66. Clustered and persistent selling at this cadence from an operating executive is unusual, though low trade-significance scores suggest these may reflect a structured disposal plan rather than discretionary selling. The 90-day net figure across all insiders shows more than 577,000 net shares sold and over $8.2 million in net value — firmly in net-sell territory.
On the Street, analysts reacted to the Q1 earnings print on May 6 with largely positive but measured moves. JP Morgan's Sebastian Sandler trimmed his price target to $19 from $21 while keeping an Overweight rating — acknowledging the MRD revenue guidance cut but staying constructive. TD Cowen's Dan Brennan went the other way, lifting his target to $21 from $19 while reiterating Buy. BTIG and Guggenheim held their respective $22 and $21 Buy-rated targets. The consensus mean price target of roughly $20.30 implies around 47% upside from the current $13.78 close. The bull case centres on rising clonoSEQ test volumes, improving average selling prices toward $1,700–$1,800 by 2029, and margin expansion from NovaSeq X adoption. The bear case is harder to ignore: MRD revenue guidance was cut to $8–9 million for 2026, down sharply from $19.5 million in 2025, and clinical milestone payments are set to decline 56% year-on-year. EPS momentum factor scores are weak — ranking in the 20th percentile on a 30-day basis and the 14th percentile over 90 days.
Close correlated peers had a mixed session on May 5. RVTY and RGEN both rose more than 6% on the day and 7–8% on the week, while PSNL fell almost 6%. ADPT's own 5% single-day decline on May 5 — the day of its earnings release — stands out against that backdrop. The next scheduled event is June 5, when the company reports again.
The key question heading into June is whether the MRD revenue trajectory stabilises or deteriorates further — and whether the pace of COO share sales continues at the same clip.
See the live data behind this article on ORTEX.
Open ADPT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
